S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
S&P 500   3,783.28
DOW   30,273.87
QQQ   281.98
5 Tips I Wish I Knew Before Starting My Business
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Live Updates: Russia-Ukraine War
Too Soon: 3 Reasons to Wait on DocuSign Stock
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)pixel
OPEC+ makes big oil cut to boost prices; pump costs may rise
WTO predicts trade growth to slow next year amid crises
The Safest Option in Trades! (Ad)pixel
Stocks slump as Wall Street’s big rally fades, yields rise
Rite-Aid Sings a Familiar Tune That Investors Don’t Want to Hear
NASDAQ:IRWD

Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

$10.47
-0.13 (-1.23%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.37
$10.64
50-Day Range
$10.14
$12.38
52-Week Range
$10.01
$14.21
Volume
1.95 million shs
Average Volume
2.36 million shs
Market Capitalization
$1.60 billion
P/E Ratio
10.37
Dividend Yield
N/A
Price Target
$14.50

Ironwood Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
38.5% Upside
$14.50 Price Target
Short Interest
Bearish
12.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.94
Upright™ Environmental Score
News Sentiment
0.93mentions of Ironwood Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.50 M Sold Last Quarter
Proj. Earnings Growth
28.57%
From $0.98 to $1.26 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

163rd out of 1,072 stocks

Pharmaceutical Preparations Industry

66th out of 534 stocks

IRWD stock logo

About Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Stock News Headlines

See More Headlines
Receive IRWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IRWD Company Calendar

Last Earnings
8/04/2022
Today
10/06/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IRWD
CUSIP
46333X10
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.50
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+38.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$528.45 million
Pretax Margin
52.01%

Debt

Sales & Book Value

Annual Sales
$413.75 million
Cash Flow
$1.18 per share
Book Value
$3.74 per share

Miscellaneous

Free Float
133,158,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
1.00

Key Executives

  • Ms. Julie H. McHughMs. Julie H. McHugh (Age 58)
    Exec. Chairman
    Comp: $155k
  • Mr. Thomas A. McCourtMr. Thomas A. McCourt (Age 65)
    CEO & Director
    Comp: $1.57M
  • Mr. Sravan Kumar Emany (Age 44)
    Sr. VP, Principal Financial Officer & CFO
    Comp: $228.89k
  • Mr. Jason  RickardMr. Jason Rickard (Age 51)
    Sr. VP & COO
    Comp: $959.33k
  • Mr. John Minardo (Age 46)
    Sr. VP, Chief Legal Officer & Sec.
    Comp: $553.29k
  • Dr. Michael  Shetzline M.D.Dr. Michael Shetzline M.D. (Age 63)
    Ph.D., Chief Medical Officer, Sr. VP and Head of Research & Drug Devel.
    Comp: $907.94k
  • Mr. Ronald  SilverMr. Ronald Silver (Age 40)
    Corp. Controller & Principal Accounting Officer
  • Mr. Marcel Moulaison
    VP of Technical Operations
  • Ms. Beth Calitri
    Head of Corp. Communications & Media Relations
  • Mr. Mike Nanfito
    VP of Sales & Sales Excellence













IRWD Stock - Frequently Asked Questions

Should I buy or sell Ironwood Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings
or view top-rated stocks.

What is Ironwood Pharmaceuticals' stock price forecast for 2022?

4 Wall Street analysts have issued 1-year price objectives for Ironwood Pharmaceuticals' shares. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they anticipate the company's share price to reach $14.50 in the next year. This suggests a possible upside of 38.5% from the stock's current price.
View analysts price targets for IRWD
or view top-rated stocks among Wall Street analysts.

How have IRWD shares performed in 2022?

Ironwood Pharmaceuticals' stock was trading at $11.66 at the start of the year. Since then, IRWD shares have decreased by 10.2% and is now trading at $10.47.
View the best growth stocks for 2022 here
.

When is Ironwood Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our IRWD earnings forecast
.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its earnings results on Thursday, August, 4th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.10. The biotechnology company earned $97.23 million during the quarter, compared to analysts' expectations of $103.51 million. Ironwood Pharmaceuticals had a net margin of 41.65% and a trailing twelve-month return on equity of 31.01%. The business's revenue for the quarter was down 6.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.34 EPS.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $420.00 million-$430.00 million, compared to the consensus revenue estimate of $428.80 million.

What is Mark Mallon's approval rating as Ironwood Pharmaceuticals' CEO?

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $10.47.

How much money does Ironwood Pharmaceuticals make?

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.60 billion and generates $413.75 million in revenue each year. The biotechnology company earns $528.45 million in net income (profit) each year or $1.01 on an earnings per share basis.

How many employees does Ironwood Pharmaceuticals have?

The company employs 219 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.

This page (NASDAQ:IRWD) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.